000293615 001__ 293615
000293615 005__ 20250731134001.0
000293615 0247_ $$2doi$$a10.1002/ijc.35199
000293615 0247_ $$2pmid$$apmid:39319506
000293615 0247_ $$2ISSN$$a0020-7136
000293615 0247_ $$2ISSN$$a1097-0215
000293615 0247_ $$2altmetric$$aaltmetric:168599945
000293615 037__ $$aDKFZ-2024-01931
000293615 041__ $$aEnglish
000293615 082__ $$a610
000293615 1001_ $$00000-0002-9698-9559$$aWiesweg, Marcel$$b0
000293615 245__ $$aOligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.
000293615 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000293615 3367_ $$2DRIVER$$aarticle
000293615 3367_ $$2DataCite$$aOutput Types/Journal article
000293615 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1735806652_26397
000293615 3367_ $$2BibTeX$$aARTICLE
000293615 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293615 3367_ $$00$$2EndNote$$aJournal Article
000293615 500__ $$a2025 Feb 15;156(4):776-787
000293615 520__ $$aOligometastatic (OMD) non-small cell lung cancer (NSCLC) is a distinct but heterogeneous entity. Current guidelines recommend systemic therapy and consolidation with local ablative therapy (LAT). However, evidence regarding the optimal choice of multimodal treatment approaches is lacking, in particular with respect to the integration of immunotherapy. This real-world study identified 218 patients with OMD NSCLC (2004-2023, prespecified criteria: ≤5 metastases in ≤2 organ systems) from three major German comprehensive cancer centers. Most patients had one (72.5%) or two (17.4%) metastatic lesions in a single (89.9%) organ system. Overall survival (OS) was significantly longer with a single metastatic lesion (HR 0.54, p = .003), and female gender (HR 0.4, p < .001). Median OS of the full cohort was 27.8 months, with 29% survival at 5 years. Patients who had completed LAT to all NSCLC sites, typically excluding patients with early progression, had a median OS of 34.4 months (37.7% 5-year OS rate) with a median recurrence-free survival (RFS) of 10.9 months (13.3% at 5 years). In those patients, systemic treatment as part of first-line therapy was associated with doubling of RFS (12.3 vs. 6.4 months, p < .001). Despite limited follow-up of patients receiving chemo-immunotherapy (EU approval 2018/2019), RFS was greatly improved by adding checkpoint inhibitors to chemotherapy (HR 0.44, p = .008, 2-year RFS 51.4% vs. 15.1%). In conclusion, patients with OMD NSCLC benefitted from multimodality approaches integrating systemic therapy and local ablation of all cancer sites. A substantial proportion of patients achieved extended OS, suggesting a potential for cure that can be further augmented with the addition of immunotherapy.
000293615 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000293615 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000293615 650_7 $$2Other$$aimmunotherapy
000293615 650_7 $$2Other$$alocally ablative treatment
000293615 650_7 $$2Other$$amultimodal concepts
000293615 650_7 $$2Other$$aobservational study
000293615 650_7 $$2Other$$aoligometastatic NSCLC
000293615 7001_ $$aKüter, Claudia$$b1
000293615 7001_ $$aSchnorbach, Johannes$$b2
000293615 7001_ $$aKeyl, Julius$$b3
000293615 7001_ $$aMetzenmacher, Martin$$b4
000293615 7001_ $$aCvetkovic, Jelena$$b5
000293615 7001_ $$aSaalfeld, Felix Carl$$b6
000293615 7001_ $$aGlanemann, Franziska$$b7
000293615 7001_ $$00000-0003-4284-3586$$aEberhardt, Wilfried$$b8
000293615 7001_ $$aOezkan, Filiz$$b9
000293615 7001_ $$aTheegarten, Dirk$$b10
000293615 7001_ $$00000-0003-1001-103X$$aStenzinger, Albrecht$$b11
000293615 7001_ $$aDarwiche, Kaid$$b12
000293615 7001_ $$aKoschel, Dirk$$b13
000293615 7001_ $$aHerth, Felix$$b14
000293615 7001_ $$aBölükbas, Servet$$b15
000293615 7001_ $$aWinter, Hauke$$b16
000293615 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b17$$udkfz
000293615 7001_ $$aWermke, Martin$$b18
000293615 7001_ $$aStuschke, Martin$$b19
000293615 7001_ $$aPlönes, Till$$b20
000293615 7001_ $$aThomas, Michael$$b21
000293615 7001_ $$aSchuler, Martin$$b22
000293615 7001_ $$aChristopoulos, Petros$$b23
000293615 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35199$$gp. ijc.35199$$n4$$p776-787$$tInternational journal of cancer$$v156$$x0020-7136$$y2025
000293615 8564_ $$uhttps://inrepo02.dkfz.de/record/293615/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Wiesweg%20-%20Oligometastatic%20non%E2%80%90small%20cell%20lung%20cancer%20Impact%20of%20local%20and%20contemporary-1.pdf
000293615 8564_ $$uhttps://inrepo02.dkfz.de/record/293615/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Wiesweg%20-%20Oligometastatic%20non%E2%80%90small%20cell%20lung%20cancer%20Impact%20of%20local%20and%20contemporary-1.pdf?subformat=pdfa$$xpdfa
000293615 909CO $$ooai:inrepo02.dkfz.de:293615$$pVDB
000293615 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000293615 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000293615 9141_ $$y2024
000293615 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000293615 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000293615 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000293615 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000293615 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000293615 980__ $$ajournal
000293615 980__ $$aVDB
000293615 980__ $$aI:(DE-He78)E050-20160331
000293615 980__ $$aUNRESTRICTED